Skip to content

5-MeO-DMT: all studies

Page 8 of 110: studies 71 to 80 of 1,096, newest first. Back to the 5-MeO-DMT overview

Research

Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie July 9, 2025 Angela Äbelö, John W Smallridge, Robin von Rotz et al. 3 citations

N,N-dimethyltryptamine (DMT) is a psychedelic compound commonly co-administered with the monoamine oxidase inhibitor harmine in ayahuasca-inspired formulations. However, the impact of harmine on DMT pharmacokinetics (PK) and pharmacodynamics (PD) remains insufficiently characterized. In this single-blind, randomized, two-arm, factorial, dose-finding study, 16 healthy participants (9 males, 7...

DOI: 10.1016/j.biopha.2025.118329 (opens in new tab) Full text (opens in new tab) Pharmacodynamics Pharmacokinetics Psychedelics Harmine-DMT Interaction Alter +10

Effects of three tryptamines: alpha-methyltryptamine, 5-methoxy-alpha-methyltryptamine, and 5-methoxy-N,N-diisopropyltryptamine on acute toxicity, locomotor activity, and hallucinogenic behavior in mice.

Behavioural Pharmacology July 7, 2025 Kaixi Li, Nan Li, Yuanyuan Chen et al.

Alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) are synthetic tryptamines with hallucinogenic-like properties that are widely abused worldwide. There, however, has been a paucity of research and a lack of available data on their pharmacological properties. The objective of this study was to investigate the safety...

DOI: 10.1097/FBP.0000000000000841 (opens in new tab) Full text (opens in new tab) 5-methoxy-alpha-methyltryptamine Acute toxic Hallucinogenic effects Locomotor +11

Disintegration of Default Mode: Functional MRI Insights Into N,N-Dimethyltryptamine (DMT), Consciousness, and Subcortical Connectivity.

Cureus July 1, 2025 Amy Avakian

N,N-Dimethyltryptamine (DMT), a potent endogenous psychedelic, evokes rapid and immersive shifts in consciousness that challenge conventional neurocognitive models. Functional magnetic resonance imaging (fMRI) and electroencephalography (EEG)-fMRI studies suggest that these altered states are not chaotic but patterned, marked by a disruption of the default mode network (DMN), an increase in...

DOI: 10.7759/cureus.88931 (opens in new tab) Full text (opens in new tab) FMRI Neuroimaging Functional MRI FMRI Pituitary DMT Dmn

A systematic study of changes in monoamine neurotransmitters in the rat brain following acute administration of alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT).

Neuroscience Research July 1, 2025 Kaixi Li, Nan Li, Yuanyuan Chen et al. 1 citation

Alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) are three synthetic tryptamines with hallucinogenic properties that are widely abused worldwide. The hallucinogenic effects of tryptamines are primarily related to activation of the 5-HT receptor, and among the many subtypes of 5-HT receptors, the 5-HT2A receptor is...

We licked the frogs so you don’t have to: A comprehensive history and analysis of the chemical syntheses of the classical psychedelics Bufotenin(e) and 5-methoxy-N,N-dimethyltryptamine

ChemRxiv June 26, 2025 Anton A. Homon, Jaxon Laramie, John J. Hayward et al. preprint

Bufotenin (also spelt as bufotenine) and its methylated derivative, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) are potent psychedelics (although the activity of the former is attenuated due to its low propensity to cross the blood-brain-barrier) that are found in many plants but also excreted by specific species of toads. The compounds are regulated differently around the world, and although...

Fear as medicine: A mixed-methods analysis of 5-MeO-DMT, mental health, and intergenerational healing

Applied Psychology Research June 26, 2025 Jeffrey Overall

Objective: This study investigates the psychological mechanisms through which 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) influences mental health outcomes, with a focus on fear confrontation, emotional release, and intergenerational trauma. Design: A qualitative methodology was employed, combining grounded theory and qualitative comparative analysis (QCA). Fourteen individuals who had...

Investigating the Synergistic Neuroprotective Effects of Plant-Derived Antioxidants and the Psychedelic N,N-Dimethyltryptamine in Alzheimer's Disease Therapy.

Cells June 19, 2025 Júlia Jarne-Ferrer, Mercè Pallàs, Christian Griñán-Ferré et al. 2 citations

Alzheimer's disease (AD) is a chronic and complex neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and irreversible impairment of brain functions. The etiology of AD is multifactorial, involving a complex interplay of genetic, environmental, and physiological factors, including the aggregation of amyloid-β (Aβ) and oxidative stress (OS). The role of OS in...

Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial.

European Neuropsychopharmacology June 17, 2025 Isabel Wießner, Marcelo Falchi-Carvalho, Sophie Laborde et al. 7 citations

Vaporized N,N-Dimethyltryptamine (DMT) has a short duration and simple application, prompting this technique as a new approach for psychedelics' clinical use. Building on our initial dose-ascending studies and addressing potential confounding effects of dosing order, this study is the first to evaluate inhaled DMT in a randomized, placebo-controlled, double-blind design. Given DMT's therapeutic...

DOI: 10.1016/j.euroneuro.2025.06.002 (opens in new tab) Full text (opens in new tab) Psychedelic therapy N,N-Dimethyltryptamine Placebo-controlled study Psychedelics +17

Treating War Trauma with Ibogaine and 5-MEO-DMT

June 16, 2025 María José Polanco, Mark D. Black

This chapter details the therapy protocols involving ibogaine utilized at The Mission Within (https://missionwithin.org) in Baja California, Mexico, as described by its founder and research director, Dr. Martin Polanco, along with psychedelic preparation/integration counselor and therapeutic facilitator, Dr. Mia Black. The chapter describes: Their personal development as ibogaine therapists and...

Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression.

Metabolic Brain Disease June 11, 2025 Daniel do Nascimento Sousa, Monique de Azevedo, Maria Lucília Santos et al. 5 citations

Ayahuasca (Aya) is an Amazonian beverage traditionally used as medicine by Indigenous people in South America to treat various illnesses and have shown a potential to treat depression. This study aimed to investigate the antidepressant effects of fluoxetine, Aya and N, N dimethyl tryptamine (DMT), a component of the beverage, focusing on the modulation of inflammatory serum cytokine profiles...